Cargando…

Efficacy and safety of Echinaforce® in respiratory tract infections

Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinafor...

Descripción completa

Detalles Bibliográficos
Autor principal: Schapowal, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088131/
https://www.ncbi.nlm.nih.gov/pubmed/23263637
http://dx.doi.org/10.1007/s10354-012-0166-0
_version_ 1783509478683967488
author Schapowal, Andreas
author_facet Schapowal, Andreas
author_sort Schapowal, Andreas
collection PubMed
description Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment.
format Online
Article
Text
id pubmed-7088131
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-70881312020-03-23 Efficacy and safety of Echinaforce® in respiratory tract infections Schapowal, Andreas Wien Med Wochenschr Main Topic Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment. Springer Vienna 2012-12-20 2013 /pmc/articles/PMC7088131/ /pubmed/23263637 http://dx.doi.org/10.1007/s10354-012-0166-0 Text en © Springer-Verlag Wien 2012 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Main Topic
Schapowal, Andreas
Efficacy and safety of Echinaforce® in respiratory tract infections
title Efficacy and safety of Echinaforce® in respiratory tract infections
title_full Efficacy and safety of Echinaforce® in respiratory tract infections
title_fullStr Efficacy and safety of Echinaforce® in respiratory tract infections
title_full_unstemmed Efficacy and safety of Echinaforce® in respiratory tract infections
title_short Efficacy and safety of Echinaforce® in respiratory tract infections
title_sort efficacy and safety of echinaforce® in respiratory tract infections
topic Main Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088131/
https://www.ncbi.nlm.nih.gov/pubmed/23263637
http://dx.doi.org/10.1007/s10354-012-0166-0
work_keys_str_mv AT schapowalandreas efficacyandsafetyofechinaforceinrespiratorytractinfections